| AMERISOURCEBERGEN-HEALTH-CORPORATION |
AMERISOURCEBERGEN-HEALTH-CORPORATION |
92%
|
Significant Customers We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2024: McKesson Drug Company, Cardinal Health, Inc. and Amerisour… |
| MCKESSON-DRUG-COMPANY |
MCKESSON-DRUG-COMPANY |
92%
|
Significant Customers We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2024: McKesson Drug Company, Cardinal Health, Inc. and Amerisour… |
| GQ-BIO-THERAPEUTICS-GMBH |
GQ-BIO-THERAPEUTICS-GMBH |
85%
|
evelopment of PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like OA… |
| JNJ |
Johnson & Johnson |
85%
|
025, of which $ million are due in each of 2026 and 2027, $ million in 2028, and $ million in each of 2028 and 2029. The Company has $ million of other minimum, non-cancelable contractual commitments… |
| JNJ |
Johnson & Johnson |
85%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from PCRX graph: 025, of which $ million are due in each of 2026 and 2027, $ million in 2028, and $ million in each of 2028 and 2029. T… |
| AVNS |
Avanos Medical, Inc. |
72%
|
Reciprocal relationship from AVNS graph: Reciprocal relationship from PCRX graph: ers of EXPAREL, ZILRETTA or iovera° that accounted for 10 percent or more of our total revenue for the year ended Dec… |
| AVNS |
Avanos Medical, Inc. |
72%
|
ers of EXPAREL, ZILRETTA or iovera° that accounted for 10 percent or more of our total revenue for the year ended December 31, 2025. Manufacturing and Research Facilities Internal Facilities We manuf… |
| CAH |
Cardinal Health, Inc. |
72%
|
Reciprocal relationship from CAH graph: Reciprocal relationship from PCRX graph: s of the partnership, LG Chem has the exclusive rights to commercialize EXPAREL in the region. We received a $2.0 mill… |
| CAH |
Cardinal Health, Inc. |
72%
|
s of the partnership, LG Chem has the exclusive rights to commercialize EXPAREL in the region. We received a $2.0 million upfront payment that we will recognize over the license term upon commerciali… |
| HRTX |
Heron Therapeutics, Inc. |
72%
|
Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multi… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from PCRX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from PCRX graph: ers of EXPAREL, ZILRETTA or iover… |
| ORANY |
ORANY |
72%
|
ers of EXPAREL, ZILRETTA or iovera° that accounted for 10 percent or more of our total revenue for the year ended December 31, 2025. Manufacturing and Research Facilities Internal Facilities We manuf… |
| AMERISOURCEBERGEN-HEALTH-CORPORATION-CARDINAL-HE |
AMERISOURCEBERGEN-HEALTH-CORPORATION-CARDINAL-HE |
62%
|
s With Customers The Company’s net product sales consist of (i) EXPAREL in the U.S., European Union, or E.U., and the U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera° in the U.S., Canada and Europe and… |
| ARATANA-THERAPEUTICS-INC |
ARATANA-THERAPEUTICS-INC |
62%
|
-facing team, consisting of sales representatives, account managers, scientific and medical affairs personnel and reimbursement and market access professionals, executes on a full range of activities… |
| CAPPED-CALL-TRANSACTIONS-PACIRA-BIOSCIENCES-INC |
CAPPED-CALL-TRANSACTIONS-PACIRA-BIOSCIENCES-INC |
62%
|
.2 million. Intangible Assets Intangible assets, net, consists of in-process research and development, or IPR&D, from the GQ Bio Acquisition and Flexion Acquisition, developed technology from the Fle… |
| CARLISLE-COMPANIES-INC |
CARLISLE-COMPANIES-INC |
62%
|
ZILRETTA or iovera° accounted for 10 percent or more of our total revenue for the year ended December 31, 2024. Manufacturing and Research Facilities Internal Facilities We manufacture EXPAREL and io… |
| ELANCO-ANIMAL-HEALTH-INC |
ELANCO-ANIMAL-HEALTH-INC |
62%
|
-facing team, consisting of sales representatives, account managers, scientific and medical affairs personnel and reimbursement and market access professionals, executes on a full range of activities… |
| FRESENIUS-KABI-USA-LLC |
FRESENIUS-KABI-USA-LLC |
62%
|
ZILRETTA or iovera° accounted for 10 percent or more of our total revenue for the year ended December 31, 2024. Manufacturing and Research Facilities Internal Facilities We manufacture EXPAREL and io… |
| FURTHER-PACIRA-BIOSCIENCES-INC |
FURTHER-PACIRA-BIOSCIENCES-INC |
62%
|
uently suspended for 30 days in order to facilitate negotiations. As of the date of this Annual Report, the proposed tariffs on all imports from Mexico remain suspended. Our iovera° tips are made in … |
| IT-PACIRA-BIOSCIENCES-INC |
IT-PACIRA-BIOSCIENCES-INC |
62%
|
on. PCRX-201 is the lead program from this platform. It Pacira BioSciences, Inc. | 2024 Annual Report on Form 10-K | Page 75 Table of Contents provides financial benefits with the elimination of futu… |
| JIANGSU-HENGRUI-PACIRA-BIOSCIENCES-INC |
JIANGSU-HENGRUI-PACIRA-BIOSCIENCES-INC |
62%
|
ZILRETTA or iovera° accounted for 10 percent or more of our total revenue for the year ended December 31, 2024. Manufacturing and Research Facilities Internal Facilities We manufacture EXPAREL and io… |
| KNEE-OA-GENASCENCE-CORPORATION |
KNEE-OA-GENASCENCE-CORPORATION |
62%
|
he strategic investments we have made to support promising early-stage platforms are summarized below: Company Development Stage Description of Platform Technology Potential Therapeutic Areas Carthro… |
| KNEE-OA-SPINE-BIOPHARMA-LLC |
KNEE-OA-SPINE-BIOPHARMA-LLC |
62%
|
he strategic investments we have made to support promising early-stage platforms are summarized below: Company Development Stage Description of Platform Technology Potential Therapeutic Areas Carthro… |
| MCKESSON-DRUG-COMPANY-CARDINAL-HEALTH-INC |
MCKESSON-DRUG-COMPANY-CARDINAL-HEALTH-INC |
62%
|
elivering a validatable manufacturing process and validated analytical control package necessary for initiating process validation. In February 2025, Pacira Therapeutics, Inc., a wholly-owned subsidi… |
| MOLEX-ASIA-HOLDINGS-LTD |
MOLEX-ASIA-HOLDINGS-LTD |
62%
|
NOTE 7— GOODWILL AND INTANGIBLE ASSETS Goodwill The Company’s goodwill arose from the GQ Bio Acquisition in February 2025. As of March 31, 2026 and December 31, 2025, the goodwill balance was $ 19.8 … |
| OYSTER-ACQUISITION-COMPANY-INC |
OYSTER-ACQUISITION-COMPANY-INC |
62%
|
-facing team, consisting of sales representatives, account managers, scientific and medical affairs personnel and reimbursement and market access professionals, executes on a full range of activities… |
| PHARMACEUTICAL-LABORATORIES-INC |
PHARMACEUTICAL-LABORATORIES-INC |
62%
|
ZILRETTA or iovera° accounted for 10 percent or more of our total revenue for the year ended December 31, 2024. Manufacturing and Research Facilities Internal Facilities We manufacture EXPAREL and io… |
| PLATFORM-TECHNOLOGY-POTENTIAL-THERAPEUTIC-AREAS- |
PLATFORM-TECHNOLOGY-POTENTIAL-THERAPEUTIC-AREAS- |
62%
|
he strategic investments we have made to support promising early-stage platforms are summarized below: Company Development Stage Description of Platform Technology Potential Therapeutic Areas Carthro… |
| POSTOPERATIVE-OPIOID-PACIRA-BIOSCIENCES-INC |
POSTOPERATIVE-OPIOID-PACIRA-BIOSCIENCES-INC |
62%
|
osomal Bupivacaine on Postoperative Opioid Pacira BioSciences, Inc. | 2024 Annual Report on Form 10-K | Page 9 Table of Contents Prescribing After Third Molar Extraction , was published in The Journa… |
| SKYEPHARMA-HOLDING-INC |
SKYEPHARMA-HOLDING-INC |
62%
|
NOTE 7— GOODWILL AND INTANGIBLE ASSETS Goodwill The Company’s goodwill arose from the GQ Bio Acquisition in February 2025. As of March 31, 2026 and December 31, 2025, the goodwill balance was $ 19.8 … |
